IPO registrations (S-1, F-1) · Registrants
Erasca, Inc.
- SEC CIK
- 1761918 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-06-25, last 2021-07-12; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2021-07-16; declared effective 2021-07-15
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 3115 MERRYFIELD ROW, THIRD FLOOR, San Diego, CA 92121
- EIN
- 83-1217027
- Ticker
- ERAS (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Erasca, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2021-07-12)
- Final price
- $16.00 per share, within the range (424B4 filed 2021-07-16, an initial public offering)
- Shares sold
- 18,750,000
- Gross proceeds
- $300,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ERAS
- Lead underwriters
- J.P. Morgan
- Syndicate
- Morgan Stanley; BofA Securities; Evercore; Guggenheim Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: ERASCA, INC. EXACT (EIN (EXACT))
- Form D issuer: Erasca, Inc. EXACT (CIK (EXACT))
- SEC filer: Erasca, Inc. EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-06-25 | S-1 | S-1 (registration) | Erasca, Inc. | 0001193125-21-200537 ↗ |
| 2021-07-12 | S-1/A | S-1/A (amendment) | Erasca, Inc. | 0001193125-21-212361 ↗ |
| 2021-07-15 | S-1MEF | S-1MEF (added securities) | Erasca, Inc. | 0001193125-21-216695 ↗ |
| 2021-07-15 | EFFECT | EFFECT (declared effective) | Erasca, Inc. | 9999999995-21-002792 ↗ |
| 2021-07-16 | 424B4 | 424B4 (final prospectus) | Erasca, Inc. | 0001193125-21-217534 ↗ |
| 2022-08-18 | EFFECT | EFFECT (declared effective) | Erasca, Inc. | 9999999995-22-002436 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-12 | S-1/A | registration statement | $14.00–$16.00 | 17,500,000 | - | Nasdaq ERAS | 5 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 5 | document ↗ | |
| 2021-07-16 | 424B4 | final prospectus | $16.00 | 18,750,000 | $300,000,000 | Nasdaq ERAS | 5 | primary document; price sentence, shares headline, proceeds table, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | TenPercentOwner | 2 | 2021 | ||
| ARCH Venture Fund X Overage, L.P. | TenPercentOwner | 2 | 2021 | ||
| ARCH Venture Partners X, LLC | TenPercentOwner | 2 | 2021 | ||
| ARCH Venture Partners X, L.P. | TenPercentOwner | 2 | 2021 | ||
| ARCH Venture Partners X Overage, L.P. | TenPercentOwner | 2 | 2021 | ||
| Bristol James Arthur | Director | 10 | 2021–2026 | ||
| Burow Kristina | TenPercentOwner | 2 | 2021 | ||
| Casdin Alexander W. | Director | 15 | 2021–2026 | ||
| Chacko David M. | Officer | CFO and CBO; Chief Financial Officer | 8 | 2021–2026 | |
| Chen Bihua | Director; Director,TenPercentOwner | 8 | 2021–2023 | ||
| City Hill, LLC | TenPercentOwner | 2 | 2021 | ||
| Cormorant Asset Management, LP | Director; TenPercentOwner | 6 | 2021–2023 | ||
| Cormorant Global Healthcare Master Fund, LP | Director; TenPercentOwner | 6 | 2021–2023 | ||
| Cormorant Private Healthcare Fund II, LP | Director; TenPercentOwner | 6 | 2021–2023 | ||
| CRANDELL KEITH | TenPercentOwner | 2 | 2021 | ||
| Garner Ebun | Officer | Chief Legal Officer; General Counsel; General Counsel & Corp. Sec. | 12 | 2021–2026 | |
| GILLIS STEVEN | TenPercentOwner | 2 | 2021 | ||
| Hambleton Julie | Director | 7 | 2021–2026 | ||
| Lim Conyee T. | TenPercentOwner | 2 | 2021 | ||
| Lim Jonathan E | Director,Officer; Director,Officer,TenPercentOwner | Chairman and CEO; Chairman & CEO; See Remarks | 16 | 2021–2026 | |
| Multani Pratik S | Director | 10 | 2021–2026 | ||
| NELSEN ROBERT | TenPercentOwner | 2 | 2021 | ||
| Start Valerie Denise Harding | Director | 12 | 2021–2026 | ||
| Varney Michael David | Director | 6 | 2021–2026 | ||
| Wei Lin | Officer | Chief Medical Officer | 3 | 2021–2023 | |
| LIU JEAN I | Director | 9 | 2022–2026 | ||
| Morris Shannon | Officer | Chief Medical Officer | 7 | 2023–2026 | |
| Fuchs Charles S. | Officer | President, R&D | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-04-30 | Erasca, Inc. | Biotechnology | $374,536,960 | $125,405,005 | 46 | 1 |
| 2019-01-15 | Erasca, Inc. | Biotechnology | $70,000,000 | $58,278,287 | 41 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | ERASCA, INC. | CA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Erasca, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Erasca, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | ERASCA, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
- CymaBay Therapeutics, Inc. CA
- CRESCENDO PHARMACEUTICALS CORP CA
- SPIROS DEVELOPMENT CORP II INC CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health